Macfarlanes advises SV Health Investors on closing of SV7 Impact Medicine Fund

Macfarlanes has advised financial institution SV Health Investors on the raising of its first biotech fund, which has closed at its hard cap of $265m.

The IMF is SV’s first dedicated biotech fund and it will aim to turn scientific breakthroughs into biotech companies producing high impact precision medicine drugs for poorly treated diseases.

The fund secured investments from pharmaceutical companies, family offices, pension funds and charities such as Cancer Research UK.

The Macfarlanes team for this matter was led by investment management partner Stephen Robinson with assistance from senior solicitor Harriet Miller and solicitor Sweta Tandle. Tax advice was provided by partner Mark Baldwin.

Stephen Robinson comments: “We were delighted to advise SV on the successful fundraise of their first dedicated biotech fund.”